factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 211-239 | 234-239 | T28 | obese postpartum women | PROCESS_OF | 211 | 239 | preserve | 211-216 | 211-216 | T16 | obese | DiseaseOrSyndrome | 211 | 216 | preserve | 217-239 | 234-239 | T17 | postpartum women | PatientOrDisabledGroup | 217 | 239 | A10 | This secondary analysis of a longitudinal, nonintervention study describes the nutritional and physical activity behavior of overweight and obese postpartum women and the differences in nutrition and physical activity when participants are evaluated according to four weight categories: underweight, normal weight, overweight, and obese. | 65-426 | 65 | 426 | This secondary analysis of a longitudinal, nonintervention study describes the nutritional and physical activity behavior of overweight and @SUBJECT$ @PREDICAT$ @OBJECT$ and the differences in nutrition and physical activity when participants are evaluated according to four weight categories: underweight, normal weight, overweight, and obese. |
Fact | preserve | 2421-2423 | 2421-2423 | T113 | in | PROCESS_OF | 2,421 | 2,423 | preserve | 2417-2420 | 2417-2420 | T107 | MDD | MentalOrBehavioralDysfunction | 2,417 | 2,420 | preserve | 2452-2462 | 2452-2462 | T110 | inpatients | PatientOrDisabledGroup | 2,452 | 2,462 | A1 | In conclusion, venlafaxine is a cost-effective drug for the treatment of MDD in adult outpatients and inpatients. | 2338-2463 | 2,338 | 2,463 | In conclusion, venlafaxine is a cost-effective drug for the treatment of @SUBJECT$ @PREDICAT$ adult outpatients and @OBJECT$ . |
Fact | preserve | 2404-2413 | 2404-2413 | T112 | treatment | TREATS | 2,404 | 2,413 | preserve | 2391-2395 | 2391-2395 | T105 | drug | PharmacologicSubstance | 2,391 | 2,395 | preserve | 2417-2420 | 2417-2420 | T107 | MDD | MentalOrBehavioralDysfunction | 2,417 | 2,420 | A2 | In conclusion, venlafaxine is a cost-effective drug for the treatment of MDD in adult outpatients and inpatients. | 2338-2463 | 2,338 | 2,463 | In conclusion, venlafaxine is a cost-effective @SUBJECT$ for the @PREDICAT$ of @OBJECT$ in adult outpatients and inpatients. |
Fact | preserve | 1593-1625 | 1614-1625 | T74 | patients (2380 outpatients | ISA | 1,593 | 1,625 | preserve | 1634-1644 | 1634-1644 | T73 | inpatients | PatientOrDisabledGroup | 1,634 | 1,644 | preserve | 1593-1601 | 1593-1601 | T71 | patients | PatientOrDisabledGroup | 1,593 | 1,601 | A3 | The meta-analysis identified 56 treatment arms from 36 randomised controlled trials involving 2953 patients (2380 outpatients and 573 inpatients). | 1488-1646 | 1,488 | 1,646 | The meta-analysis identified 56 treatment arms from 36 randomised controlled trials involving 2953 @OBJECT$ @PREDICAT$ and 573 @SUBJECT$ ). |
Fact | preserve | 1211-1214 | 1211-1214 | T55 | for | TREATS | 1,211 | 1,214 | preserve | 1203-1210 | 1203-1210 | T50 | therapy | TherapeuticOrPreventiveProcedure | 1,203 | 1,210 | preserve | 1215-1223 | 1215-1223 | T51 | patients | PatientOrDisabledGroup | 1,215 | 1,223 | A5 | SSRIs were used as backup therapy for patients receiving venlafaxine and TCAs, and SNRIs were used as backup therapy for patients receiving SSRIs. | 1170-1329 | 1,170 | 1,329 | SSRIs were used as backup @SUBJECT$ @PREDICAT$ @OBJECT$ receiving venlafaxine and TCAs, and SNRIs were used as backup therapy for patients receiving SSRIs. |
Fact | preserve | 1593-1625 | 1614-1625 | T74 | patients (2380 outpatients | ISA | 1,593 | 1,625 | preserve | 1614-1625 | 1614-1625 | T72 | outpatients | PatientOrDisabledGroup | 1,614 | 1,625 | preserve | 1593-1601 | 1593-1601 | T71 | patients | PatientOrDisabledGroup | 1,593 | 1,601 | A7 | The meta-analysis identified 56 treatment arms from 36 randomised controlled trials involving 2953 patients (2380 outpatients and 573 inpatients). | 1488-1646 | 1,488 | 1,646 | The meta-analysis identified 56 treatment arms from 36 randomised controlled trials involving 2953 @OBJECT$ @PREDICAT$ @SUBJECT$ and 573 inpatients). |
Fact | preserve | 1300-1303 | 1300-1303 | T57 | for | TREATS | 1,300 | 1,303 | preserve | 1292-1299 | 1292-1299 | T53 | therapy | TherapeuticOrPreventiveProcedure | 1,292 | 1,299 | preserve | 1304-1312 | 1304-1312 | T54 | patients | PatientOrDisabledGroup | 1,304 | 1,312 | A8 | SSRIs were used as backup therapy for patients receiving venlafaxine and TCAs, and SNRIs were used as backup therapy for patients receiving SSRIs. | 1170-1329 | 1,170 | 1,329 | SSRIs were used as backup therapy for patients receiving venlafaxine and TCAs, and SNRIs were used as backup @SUBJECT$ @PREDICAT$ @OBJECT$ receiving SSRIs. |
Fact | preserve | 2359-2395 | 2391-2395 | T111 | venlafaxine is a cost-effective drug | ISA | 2,359 | 2,395 | preserve | 2359-2370 | 2359-2370 | T103 | venlafaxine | OrganicChemical | 2,359 | 2,370 | preserve | 2391-2395 | 2391-2395 | T105 | drug | PharmacologicSubstance | 2,391 | 2,395 | A10 | In conclusion, venlafaxine is a cost-effective drug for the treatment of MDD in adult outpatients and inpatients. | 2338-2463 | 2,338 | 2,463 | In conclusion, @SUBJECT$ @PREDICAT$ @OBJECT$ for the treatment of MDD in adult outpatients and inpatients. |
Fact | preserve | 48-57 | 48-57 | T5 | treatment | TREATS | 48 | 57 | preserve | 29-40 | 29-40 | T2 | venlafaxine | OrganicChemical | 29 | 40 | preserve | 61-92 | 84-92 | T4 | major depressive disorder | MentalOrBehavioralDysfunction | 61 | 92 | A11 | Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. | 0-93 | 0 | 93 | Pharmacoeconomic analysis of @SUBJECT$ in the @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 2421-2423 | 2421-2423 | T113 | in | PROCESS_OF | 2,421 | 2,423 | preserve | 2417-2420 | 2417-2420 | T107 | MDD | MentalOrBehavioralDysfunction | 2,417 | 2,420 | preserve | 2436-2447 | 2436-2447 | T109 | outpatients | PatientOrDisabledGroup | 2,436 | 2,447 | A12 | In conclusion, venlafaxine is a cost-effective drug for the treatment of MDD in adult outpatients and inpatients. | 2338-2463 | 2,338 | 2,463 | In conclusion, venlafaxine is a cost-effective drug for the treatment of @SUBJECT$ @PREDICAT$ adult @OBJECT$ and inpatients. |
Fact | preserve | 1224-1233 | 1224-1233 | T56 | receiving | ADMINISTERED_TO | 1,224 | 1,233 | preserve | 1234-1245 | 1234-1245 | T52 | venlafaxine | OrganicChemical | 1,234 | 1,245 | preserve | 1215-1223 | 1215-1223 | T51 | patients | PatientOrDisabledGroup | 1,215 | 1,223 | A15 | SSRIs were used as backup therapy for patients receiving venlafaxine and TCAs, and SNRIs were used as backup therapy for patients receiving SSRIs. | 1170-1329 | 1,170 | 1,329 | SSRIs were used as backup therapy for @OBJECT$ @PREDICAT$ @SUBJECT$ and TCAs, and SNRIs were used as backup therapy for patients receiving SSRIs. |
Fact | preserve | 2359-2395 | 2391-2395 | T115 | venlafaxine is a cost-effective drug | TREATS | 2,359 | 2,395 | preserve | 2359-2370 | 2359-2370 | T103 | venlafaxine | OrganicChemical | 2,359 | 2,370 | preserve | 2417-2420 | 2417-2420 | T107 | MDD | MentalOrBehavioralDysfunction | 2,417 | 2,420 | A16 | In conclusion, venlafaxine is a cost-effective drug for the treatment of MDD in adult outpatients and inpatients. | 2338-2463 | 2,338 | 2,463 | In conclusion, @SUBJECT$ @PREDICAT$ for the treatment of @OBJECT$ in adult outpatients and inpatients. |
Fact | preserve | 2068-2085 | 2077-2085 | T116 | diabetic patients | PROCESS_OF | 2,068 | 2,085 | preserve | 2068-2076 | 2068-2076 | T112 | diabetic | Finding | 2,068 | 2,076 | preserve | 2077-2085 | 2077-2085 | T113 | patients | PatientOrDisabledGroup | 2,077 | 2,085 | A1 | These findings have important clinical implications for diabetic patients with congestive heart failure. | 2006-2116 | 2,006 | 2,116 | These findings have important clinical implications for @SUBJECT$ @PREDICAT$ @OBJECT$ with congestive heart failure. |
Counterfact | preserve | 1945-1953 | 1945-1953 | T108 | mediated | INTERACTS_WITH | 1,945 | 1,953 | preserve | 1924-1936 | 1924-1936 | T103 | troglitazone | OrganicChemical | 1,924 | 1,936 | preserve | 1958-1978 | 1969-1978 | T106 | adrenergic receptors | AminoAcidPeptideOrProtein | 1,958 | 1,978 | A2 | The inotropic and chronotropic actions of troglitazone are not mediated via adrenergic receptors or calcium channels. | 1876-2005 | 1,876 | 2,005 | The inotropic and chronotropic actions of @SUBJECT$ are not @PREDICAT$ via @OBJECT$ or calcium channels. |
Counterfact | preserve | 1945-1953 | 1945-1953 | T108 | mediated | INTERACTS_WITH | 1,945 | 1,953 | preserve | 1924-1936 | 1924-1936 | T103 | troglitazone | OrganicChemical | 1,924 | 1,936 | preserve | 1988-2004 | 1996-2004 | T107 | calcium channels | AminoAcidPeptideOrProtein | 1,988 | 2,004 | A3 | The inotropic and chronotropic actions of troglitazone are not mediated via adrenergic receptors or calcium channels. | 1876-2005 | 1,876 | 2,005 | The inotropic and chronotropic actions of @SUBJECT$ are not @PREDICAT$ via adrenergic receptors or @OBJECT$ . |
Fact | preserve | 40-47 | 40-47 | T10 | effects | AFFECTS | 40 | 47 | preserve | 51-63 | 51-63 | T5 | troglitazone | OrganicChemical | 51 | 63 | preserve | 95-101 | 95-101 | T9 | hearts | BodyPartOrganOrOrganComponent | 95 | 101 | A4 | Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. | 0-102 | 0 | 102 | Hemodynamic basis for the acute cardiac @PREDICAT$ of @SUBJECT$ in isolated perfused rat @OBJECT$ . |
Uncommitted | preserve | 577-584 | 577-584 | T41 | effects | AFFECTS | 577 | 584 | preserve | 588-600 | 588-600 | T36 | troglitazone | OrganicChemical | 588 | 600 | preserve | 632-638 | 632-638 | T40 | hearts | BodyPartOrganOrOrganComponent | 632 | 638 | A6 | Therefore, we investigated the direct cardiac hemodynamic effects of troglitazone in isolated perfused rat hearts. | 513-639 | 513 | 639 | Therefore, we investigated the direct cardiac hemodynamic @PREDICAT$ of @SUBJECT$ in isolated perfused rat @OBJECT$ . |
Fact | preserve | 628-638 | 632-638 | T42 | rat hearts | PART_OF | 628 | 638 | preserve | 632-638 | 632-638 | T40 | hearts | BodyPartOrganOrOrganComponent | 632 | 638 | preserve | 628-631 | 628-631 | T39 | rat | Mammal | 628 | 631 | A7 | Therefore, we investigated the direct cardiac hemodynamic effects of troglitazone in isolated perfused rat hearts. | 513-639 | 513 | 639 | Therefore, we investigated the direct cardiac hemodynamic effects of troglitazone in isolated perfused @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 152-161 | 152-161 | T20 | treatment | TREATS | 152 | 161 | preserve | 121-138 | 121-138 | T13 | thiazolidinedione | OrganicChemical | 121 | 138 | preserve | 165-170 | 165-170 | T15 | NIDDM | DiseaseOrSyndrome | 165 | 170 | A9 | Troglitazone is a thiazolidinedione used for the treatment of NIDDM and potentially for other insulin-resistant disease states. | 103-236 | 103 | 236 | Troglitazone is a @SUBJECT$ used for the @PREDICAT$ of @OBJECT$ and potentially for other insulin-resistant disease states. |
Fact | preserve | 103-138 | 121-138 | T19 | Troglitazone is a thiazolidinedione | ISA | 103 | 138 | preserve | 103-115 | 103-115 | T12 | Troglitazone | OrganicChemical | 103 | 115 | preserve | 121-138 | 121-138 | T13 | thiazolidinedione | OrganicChemical | 121 | 138 | A10 | Troglitazone is a thiazolidinedione used for the treatment of NIDDM and potentially for other insulin-resistant disease states. | 103-236 | 103 | 236 | @SUBJECT$ @PREDICAT$ @OBJECT$ used for the treatment of NIDDM and potentially for other insulin-resistant disease states. |
Fact | preserve | 283-291 | 283-291 | T27 | increase | AUGMENTS | 283 | 291 | preserve | 237-249 | 237-249 | T22 | Troglitazone | OrganicChemical | 237 | 249 | preserve | 311-324 | 318-324 | T25 | stroke volume | Finding | 311 | 324 | A11 | Troglitazone has recently been shown to increase cardiac output and stroke volume in human subjects. | 237-343 | 237 | 343 | @SUBJECT$ has recently been shown to @PREDICAT$ cardiac output and @OBJECT$ in human subjects. |
Fact | preserve | 283-291 | 283-291 | T27 | increase | AUGMENTS | 283 | 291 | preserve | 237-249 | 237-249 | T22 | Troglitazone | OrganicChemical | 237 | 249 | preserve | 292-306 | 300-306 | T24 | cardiac output | Finding | 292 | 306 | A12 | Troglitazone has recently been shown to increase cardiac output and stroke volume in human subjects. | 237-343 | 237 | 343 | @SUBJECT$ has recently been shown to @PREDICAT$ @OBJECT$ and stroke volume in human subjects. |
Fact | preserve | 820-832 | 820-832 | T55 | administered | USES | 820 | 832 | preserve | 842-851 | 842-851 | T54 | injection | TherapeuticOrPreventiveProcedure | 842 | 851 | preserve | 768-780 | 768-780 | T51 | troglitazone | OrganicChemical | 768 | 780 | A13 | Hearts were tested under isovolumetric contraction with a constant coronary flow, and troglitazone (0.2, 0.5, and 1.0 micromol) was administered by bolus injection. | 676-852 | 676 | 852 | Hearts were tested under isovolumetric contraction with a constant coronary flow, and @OBJECT$ (0.2, 0.5, and 1.0 micromol) was @PREDICAT$ by bolus @SUBJECT$ . |
Fact | preserve | 91-101 | 95-101 | T11 | rat hearts | PART_OF | 91 | 101 | preserve | 95-101 | 95-101 | T9 | hearts | BodyPartOrganOrOrganComponent | 95 | 101 | preserve | 91-94 | 91-94 | T8 | rat | Mammal | 91 | 94 | A14 | Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. | 0-102 | 0 | 102 | Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 103-138 | 121-138 | T21 | Troglitazone is a thiazolidinedione | TREATS | 103 | 138 | preserve | 103-115 | 103-115 | T12 | Troglitazone | OrganicChemical | 103 | 115 | preserve | 165-170 | 165-170 | T15 | NIDDM | DiseaseOrSyndrome | 165 | 170 | A15 | Troglitazone is a thiazolidinedione used for the treatment of NIDDM and potentially for other insulin-resistant disease states. | 103-236 | 103 | 236 | @SUBJECT$ @PREDICAT$ used for the treatment of @OBJECT$ and potentially for other insulin-resistant disease states. |
Probable | preserve | 1864-1873 | 1864-1873 | T116 | treatment | TREATS | 1,864 | 1,873 | preserve | 1830-1840 | 1830-1840 | T108 | nefazodone | OrganicChemical | 1,830 | 1,840 | preserve | 1883-1893 | 1883-1893 | T111 | depression | Finding | 1,883 | 1,893 | A2 | CONCLUSION: Depressed HIV-seropositive outpatients respond to nefazodone comparably to other outpatient populations and have few adverse effects, suggesting that nefazodone may have a role in the treatment of depression in HIV-seropositive patients. | 1656-1923 | 1,656 | 1,923 | CONCLUSION: Depressed HIV-seropositive outpatients respond to nefazodone comparably to other outpatient populations and have few adverse effects, suggesting that @SUBJECT$ may have a role in the @PREDICAT$ of @OBJECT$ in HIV-seropositive patients. |
Fact | preserve | 598-602 | 598-602 | T38 | with | PROCESS_OF | 598 | 602 | preserve | 603-634 | 626-634 | T37 | major depressive disorder | MentalOrBehavioralDysfunction | 603 | 634 | preserve | 586-597 | 586-597 | T36 | outpatients | PatientOrDisabledGroup | 586 | 597 | A3 | This study examined the efficacy and tolerability of nefazodone in an open 12-week trial of HIV-seropositive outpatients with major depressive disorder. | 471-635 | 471 | 635 | This study examined the efficacy and tolerability of nefazodone in an open 12-week trial of HIV-seropositive @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 678-682 | 678-682 | T51 | with | PROCESS_OF | 678 | 682 | preserve | 690-722 | 714-722 | T44 | major depressive disorder | MentalOrBehavioralDysfunction | 690 | 722 | preserve | 669-677 | 669-677 | T42 | patients | PatientOrDisabledGroup | 669 | 677 | A4 | METHOD: Fifteen HIV-seropositive patients with DSM-IV major depressive disorder and a 21-item Hamilton Rating Scale for Depression (HAM-D) score of > or =18 were treated with open-label nefazodone for 12 weeks. | 636-859 | 636 | 859 | METHOD: Fifteen HIV-seropositive @OBJECT$ @PREDICAT$ DSM-IV @SUBJECT$ and a 21-item Hamilton Rating Scale for Depression (HAM-D) score of > or =18 were treated with open-label nefazodone for 12 weeks. |
Fact | preserve | 1138-1147 | 1138-1147 | T75 | receiving | ADMINISTERED_TO | 1,138 | 1,147 | preserve | 1148-1158 | 1148-1158 | T71 | nefazodone | OrganicChemical | 1,148 | 1,158 | preserve | 1129-1137 | 1129-1137 | T70 | patients | PatientOrDisabledGroup | 1,129 | 1,137 | A5 | RESULTS: Of 15 patients receiving nefazodone, 4 discontinued treatment (1 for adverse effects). | 1108-1215 | 1,108 | 1,215 | RESULTS: Of 15 @OBJECT$ @PREDICAT$ @SUBJECT$ , 4 discontinued treatment (1 for adverse effects). |
Fact | preserve | 173-175 | 173-175 | T19 | in | PROCESS_OF | 173 | 175 | preserve | 156-172 | 162-172 | T13 | major depression | MentalOrBehavioralDysfunction | 156 | 172 | preserve | 176-184 | 176-184 | T14 | patients | PatientOrDisabledGroup | 176 | 184 | A6 | BACKGROUND: Treatment studies of major depression in patients who are seropositive for the human immunodeficiency virus (HIV) have shown comparable efficacy for both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). | 123-392 | 123 | 392 | BACKGROUND: Treatment studies of @SUBJECT$ @PREDICAT$ @OBJECT$ who are seropositive for the human immunodeficiency virus (HIV) have shown comparable efficacy for both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). |
Probable | preserve | 433-437 | 433-437 | T28 | than | higher_than | 433 | 437 | preserve | 393-403 | 393-403 | T21 | Nefazodone | OrganicChemical | 393 | 403 | preserve | 438-442 | 438-442 | T23 | TCAs | OrganicChemical | 438 | 442 | A7 | Nefazodone appears to be more tolerable than TCAs and similar to SSRIs. | 393-470 | 393 | 470 | @SUBJECT$ appears to be more tolerable @PREDICAT$ @OBJECT$ and similar to SSRIs. |
Fact | preserve | 433-437 | 433-437 | T27 | than | compared_with | 433 | 437 | preserve | 393-403 | 393-403 | T21 | Nefazodone | OrganicChemical | 393 | 403 | preserve | 438-442 | 438-442 | T23 | TCAs | OrganicChemical | 438 | 442 | A8 | Nefazodone appears to be more tolerable than TCAs and similar to SSRIs. | 393-470 | 393 | 470 | @SUBJECT$ appears to be more tolerable @PREDICAT$ @OBJECT$ and similar to SSRIs. |
Fact | preserve | 56-60 | 56-60 | T10 | with | PROCESS_OF | 56 | 60 | preserve | 61-92 | 84-92 | T5 | major depressive disorder | MentalOrBehavioralDysfunction | 61 | 92 | preserve | 44-55 | 44-55 | T4 | outpatients | PatientOrDisabledGroup | 44 | 55 | A9 | Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. | 0-122 | 0 | 122 | Antidepressant efficacy in HIV-seropositive @OBJECT$ @PREDICAT$ @SUBJECT$ : an open trial of nefazodone. |
Fact | preserve | 1782-1786 | 1782-1786 | T115 | have | PROCESS_OF | 1,782 | 1,786 | preserve | 1791-1812 | 1805-1812 | T107 | adverse effects | PathologicFunction | 1,791 | 1,812 | preserve | 1695-1706 | 1695-1706 | T102 | outpatients | PatientOrDisabledGroup | 1,695 | 1,706 | A10 | CONCLUSION: Depressed HIV-seropositive outpatients respond to nefazodone comparably to other outpatient populations and have few adverse effects, suggesting that nefazodone may have a role in the treatment of depression in HIV-seropositive patients. | 1656-1923 | 1,656 | 1,923 | CONCLUSION: Depressed HIV-seropositive @OBJECT$ respond to nefazodone comparably to other outpatient populations and @PREDICAT$ few @SUBJECT$ , suggesting that nefazodone may have a role in the treatment of depression in HIV-seropositive patients. |
Fact | preserve | 24-26 | 24-26 | T9 | in | TREATS | 24 | 26 | preserve | 0-14 | 0-14 | T1 | Antidepressant | PharmacologicSubstance | 0 | 14 | preserve | 44-55 | 44-55 | T4 | outpatients | PatientOrDisabledGroup | 44 | 55 | A11 | Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. | 0-122 | 0 | 122 | @SUBJECT$ efficacy @PREDICAT$ HIV-seropositive @OBJECT$ with major depressive disorder: an open trial of nefazodone. |
Fact | preserve | 1894-1896 | 1894-1896 | T117 | in | PROCESS_OF | 1,894 | 1,896 | preserve | 1883-1893 | 1883-1893 | T111 | depression | Finding | 1,883 | 1,893 | preserve | 1914-1922 | 1914-1922 | T114 | patients | PatientOrDisabledGroup | 1,914 | 1,922 | A12 | CONCLUSION: Depressed HIV-seropositive outpatients respond to nefazodone comparably to other outpatient populations and have few adverse effects, suggesting that nefazodone may have a role in the treatment of depression in HIV-seropositive patients. | 1656-1923 | 1,656 | 1,923 | CONCLUSION: Depressed HIV-seropositive outpatients respond to nefazodone comparably to other outpatient populations and have few adverse effects, suggesting that nefazodone may have a role in the treatment of @SUBJECT$ @PREDICAT$ HIV-seropositive @OBJECT$ . |
Fact | preserve | 24-26 | 24-26 | T9 | in | TREATS | 24 | 26 | preserve | 0-14 | 0-14 | T1 | Antidepressant | PharmacologicSubstance | 0 | 14 | preserve | 61-92 | 84-92 | T5 | major depressive disorder | MentalOrBehavioralDysfunction | 61 | 92 | A13 | Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: an open trial of nefazodone. | 0-122 | 0 | 122 | @SUBJECT$ efficacy @PREDICAT$ HIV-seropositive outpatients with @OBJECT$ : an open trial of nefazodone. |
Uncommitted | preserve | 16-19 | 16-19 | T3 | for | TREATS | 16 | 19 | preserve | 1-15 | 1-15 | T1 | Plasmapheresis | TherapeuticOrPreventiveProcedure | 1 | 15 | preserve | 20-37 | 29-37 | T2 | collagen diseases | DiseaseOrSyndrome | 20 | 37 | A1 | [Plasmapheresis for collagen diseases]. | 0-39 | 0 | 39 | [ @SUBJECT$ @PREDICAT$ @OBJECT$ ]. |
Fact | preserve | 692-730 | 709-715 | T45 | DFPP to be useful as a treatment | ISA | 692 | 730 | preserve | 692-696 | 692-696 | T42 | DFPP | TherapeuticOrPreventiveProcedure | 692 | 696 | preserve | 721-730 | 721-730 | T43 | treatment | TherapeuticOrPreventiveProcedure | 721 | 730 | A2 | We suggest DFPP to be useful as a treatment for connective tissue disease. | 681-761 | 681 | 761 | We suggest @SUBJECT$ @PREDICAT$ @OBJECT$ for connective tissue disease. |
Probable | preserve | 721-730 | 721-730 | T46 | treatment | TREATS | 721 | 730 | preserve | 692-696 | 692-696 | T42 | DFPP | TherapeuticOrPreventiveProcedure | 692 | 696 | preserve | 735-760 | 753-760 | T44 | connective tissue disease | DiseaseOrSyndrome | 735 | 760 | A3 | We suggest DFPP to be useful as a treatment for connective tissue disease. | 681-761 | 681 | 761 | We suggest @SUBJECT$ to be useful as a @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 180-183 | 180-183 | T14 | for | TREATS | 180 | 183 | preserve | 132-146 | 132-146 | T10 | plasmapheresis | TherapeuticOrPreventiveProcedure | 132 | 146 | preserve | 184-211 | 202-211 | T11 | rheumatoid arthritis | DiseaseOrSyndrome | 184 | 211 | A5 | Double-filtration plasmapheresis (DFPP) has mainly been performed for rheumatoid arthritis (RA) and systemic lupus erythematosus (SEL) since 1980. | 114-267 | 114 | 267 | Double-filtration @SUBJECT$ (DFPP) has mainly been performed @PREDICAT$ @OBJECT$ (RA) and systemic lupus erythematosus (SEL) since 1980. |
Fact | preserve | 83-86 | 83-86 | T7 | for | TREATS | 83 | 86 | preserve | 49-63 | 49-63 | T5 | plasmapheresis | TherapeuticOrPreventiveProcedure | 49 | 63 | preserve | 87-112 | 105-112 | T6 | connective tissue disease | DiseaseOrSyndrome | 87 | 112 | A8 | Recently plasmapheresis has been performed for connective tissue disease. | 40-113 | 40 | 113 | Recently @SUBJECT$ has been performed @PREDICAT$ @OBJECT$ . |
Probable | preserve | 1250-1254 | 1250-1254 | T75 | role | ASSOCIATED_WITH | 1,250 | 1,254 | preserve | 1233-1238 | 1233-1238 | T65 | MC4-R | AminoAcidPeptideOrProtein | 1,233 | 1,238 | preserve | 1270-1277 | 1270-1277 | T68 | obesity | DiseaseOrSyndrome | 1,270 | 1,277 | A1 | Finally, evidence that the MC4-R may play a role in human obesity has been obtained from the identification of a dis-functional variant of the receptor in genetically obese subjects. | 1206-1400 | 1,206 | 1,400 | Finally, evidence that the @SUBJECT$ may play a @PREDICAT$ in human @OBJECT$ has been obtained from the identification of a dis-functional variant of the receptor in genetically obese subjects. |
Fact | preserve | 1264-1277 | 1270-1277 | T76 | human obesity | PROCESS_OF | 1,264 | 1,277 | preserve | 1270-1277 | 1270-1277 | T68 | obesity | DiseaseOrSyndrome | 1,270 | 1,277 | preserve | 1264-1269 | 1264-1269 | T67 | human | Human | 1,264 | 1,269 | A2 | Finally, evidence that the MC4-R may play a role in human obesity has been obtained from the identification of a dis-functional variant of the receptor in genetically obese subjects. | 1206-1400 | 1,206 | 1,400 | Finally, evidence that the MC4-R may play a role in @OBJECT$ @PREDICAT$ @SUBJECT$ has been obtained from the identification of a dis-functional variant of the receptor in genetically obese subjects. |
Fact | preserve | 316-322 | 316-322 | T23 | result | CAUSES | 316 | 322 | preserve | 367-382 | 375-382 | T21 | protein hormone | AminoAcidPeptideOrProtein | 367 | 382 | preserve | 290-297 | 290-297 | T18 | obesity | DiseaseOrSyndrome | 290 | 297 | A3 | The Avy/-agouti mouse, one of the oldest obese mouse models, is characterized by maturity-onset obesity and diabetes as a result of ectopic expression of the secreted protein hormone, agouti protein. | 188-399 | 188 | 399 | The Avy/-agouti mouse, one of the oldest obese mouse models, is characterized by maturity-onset @OBJECT$ and diabetes as a @PREDICAT$ of ectopic expression of the secreted @SUBJECT$ , agouti protein. |
Fact | preserve | 1032-1041 | 1032-1041 | T57 | inhibited | DISRUPTS | 1,032 | 1,041 | preserve | 983-991 | 983-991 | T54 | peptides | AminoAcidPeptideOrProtein | 983 | 991 | preserve | 1042-1053 | 1047-1053 | T56 | food intake | OrganismFunction | 1,042 | 1,053 | A4 | Further evidence for this hypothesis was obtained from pharmacological studies utilizing peptides with MC4-R agonist activity, that inhibited food intake (when administered intracerebrally). | 888-1090 | 888 | 1,090 | Further evidence for this hypothesis was obtained from pharmacological studies utilizing @SUBJECT$ with MC4-R agonist activity, that @PREDICAT$ @OBJECT$ (when administered intracerebrally). |
Fact | preserve | 784-788 | 784-788 | T49 | role | AFFECTS | 784 | 788 | preserve | 770-775 | 770-775 | T42 | MC4-R | AminoAcidPeptideOrProtein | 770 | 775 | preserve | 799-810 | 799-810 | T45 | homeostasis | OrganismFunction | 799 | 810 | A5 | Subsequent development of the MC4-R knockout mouse model demonstrated that MC4-R plays a role in weight homeostasis as these mice recapitulated the metabolic defects of the agouti mouse. | 689-887 | 689 | 887 | Subsequent development of the MC4-R knockout mouse model demonstrated that @SUBJECT$ plays a @PREDICAT$ in weight @OBJECT$ as these mice recapitulated the metabolic defects of the agouti mouse. |
Fact | preserve | 167-186 | 179-186 | T11 | human obesity | PROCESS_OF | 167 | 186 | preserve | 179-186 | 179-186 | T10 | obesity | DiseaseOrSyndrome | 179 | 186 | preserve | 167-172 | 167-172 | T9 | human | Human | 167 | 172 | A6 | For many years, genetically obese mouse strains have provided models for human obesity. | 94-187 | 94 | 187 | For many years, genetically obese mouse strains have provided models for @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 52-60 | 52-60 | T6 | involved | AFFECTS | 52 | 60 | preserve | 33-51 | 44-51 | T3 | signalling pathway | CellFunction | 33 | 51 | preserve | 64-75 | 69-75 | T4 | body weight | OrganismAttribute | 64 | 75 | A7 | Melanocortin-4 receptor: a novel signalling pathway involved in body weight regulation. | 0-93 | 0 | 93 | Melanocortin-4 receptor: a novel @SUBJECT$ @PREDICAT$ in @OBJECT$ regulation. |
Fact | preserve | 316-322 | 316-322 | T23 | result | CAUSES | 316 | 322 | preserve | 367-382 | 375-382 | T21 | protein hormone | AminoAcidPeptideOrProtein | 367 | 382 | preserve | 302-310 | 302-310 | T19 | diabetes | DiseaseOrSyndrome | 302 | 310 | A8 | The Avy/-agouti mouse, one of the oldest obese mouse models, is characterized by maturity-onset obesity and diabetes as a result of ectopic expression of the secreted protein hormone, agouti protein. | 188-399 | 188 | 399 | The Avy/-agouti mouse, one of the oldest obese mouse models, is characterized by maturity-onset obesity and @OBJECT$ as a @PREDICAT$ of ectopic expression of the secreted @SUBJECT$ , agouti protein. |
Probable | preserve | 433-442 | 433-442 | T36 | expressed | PART_OF | 433 | 442 | preserve | 400-414 | 407-414 | T25 | Agouti protein | AminoAcidPeptideOrProtein | 400 | 414 | preserve | 446-460 | 451-460 | T26 | hair follicles | BodyPartOrganOrOrganComponent | 446 | 460 | A9 | Agouti protein is normally expressed in hair follicles to regulate pigmentation through antagonism of the melanocortin-1 receptor, but in-vitro studies have demonstrated that the hormone also has potent antagonist activity for the melanocortin-4 receptor (MC4-R). | 400-688 | 400 | 688 | @SUBJECT$ is normally @PREDICAT$ in @OBJECT$ to regulate pigmentation through antagonism of the melanocortin-1 receptor, but in-vitro studies have demonstrated that the hormone also has potent antagonist activity for the melanocortin-4 receptor (MC4-R). |
Possible | preserve | 2335-2337 | 2335-2337 | T128 | in | TREATS | 2,335 | 2,337 | preserve | 2292-2304 | 2292-2304 | T123 | troglitazone | OrganicChemical | 2,292 | 2,304 | preserve | 2344-2352 | 2344-2352 | T126 | patients | PatientOrDisabledGroup | 2,344 | 2,352 | A1 | Bodyweight gain may be lessened by the concomitant use of metformin and troglitazone may improve glycaemic control in obese patients. | 2214-2353 | 2,214 | 2,353 | Bodyweight gain may be lessened by the concomitant use of metformin and @SUBJECT$ may improve glycaemic control @PREDICAT$ obese @OBJECT$ . |
Fact | preserve | 2088-2092 | 2088-2092 | T118 | with | USES | 2,088 | 2,092 | preserve | 2071-2087 | 2080-2087 | T111 | Combined therapy | TherapeuticOrPreventiveProcedure | 2,071 | 2,087 | preserve | 2099-2113 | 2099-2113 | T112 | sulphonylureas | OrganicChemical | 2,099 | 2,113 | A2 | Combined therapy with sulphonylureas may be more expensive and clear clinical advantages have not been consistently demonstrated. | 2071-2213 | 2,071 | 2,213 | @SUBJECT$ @PREDICAT$ @OBJECT$ may be more expensive and clear clinical advantages have not been consistently demonstrated. |
Fact | preserve | 1320-1324 | 1320-1324 | T76 | with | PROCESS_OF | 1,320 | 1,324 | preserve | 1346-1359 | 1346-1359 | T71 | complications | PathologicFunction | 1,346 | 1,359 | preserve | 1311-1319 | 1311-1319 | T70 | patients | PatientOrDisabledGroup | 1,311 | 1,319 | A3 | Reservations about insulin therapy in patients with type 2 diabetes mellitus, particularly elderly patients with cardiovascular complications, include hypoglycaemia and bodyweight gain. | 1206-1403 | 1,206 | 1,403 | Reservations about insulin therapy in patients with type 2 diabetes mellitus, particularly elderly @OBJECT$ @PREDICAT$ cardiovascular @SUBJECT$ , include hypoglycaemia and bodyweight gain. |
Possible | preserve | 2335-2337 | 2335-2337 | T128 | in | TREATS | 2,335 | 2,337 | preserve | 2292-2304 | 2292-2304 | T123 | troglitazone | OrganicChemical | 2,292 | 2,304 | preserve | 2338-2343 | 2338-2343 | T125 | obese | DiseaseOrSyndrome | 2,338 | 2,343 | A4 | Bodyweight gain may be lessened by the concomitant use of metformin and troglitazone may improve glycaemic control in obese patients. | 2214-2353 | 2,214 | 2,353 | Bodyweight gain may be lessened by the concomitant use of metformin and @SUBJECT$ may improve glycaemic control @PREDICAT$ @OBJECT$ patients. |
Fact | preserve | 1241-1243 | 1241-1243 | T74 | in | TREATS | 1,241 | 1,243 | preserve | 1233-1240 | 1233-1240 | T66 | therapy | TherapeuticOrPreventiveProcedure | 1,233 | 1,240 | preserve | 1258-1288 | 1280-1288 | T68 | type 2 diabetes mellitus | DiseaseOrSyndrome | 1,258 | 1,288 | A5 | Reservations about insulin therapy in patients with type 2 diabetes mellitus, particularly elderly patients with cardiovascular complications, include hypoglycaemia and bodyweight gain. | 1206-1403 | 1,206 | 1,403 | Reservations about insulin @SUBJECT$ @PREDICAT$ patients with @OBJECT$ , particularly elderly patients with cardiovascular complications, include hypoglycaemia and bodyweight gain. |
Fact | preserve | 1498-1502 | 1498-1502 | T85 | with | PROCESS_OF | 1,498 | 1,502 | preserve | 1503-1533 | 1525-1533 | T83 | type 1 diabetes mellitus | DiseaseOrSyndrome | 1,503 | 1,533 | preserve | 1489-1497 | 1489-1497 | T82 | patients | PatientOrDisabledGroup | 1,489 | 1,497 | A7 | However, severe hypoglycaemia occurs with considerably lower frequency than in patients with type 1 diabetes mellitus. | 1404-1534 | 1,404 | 1,534 | However, severe hypoglycaemia occurs with considerably lower frequency than in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Possible | preserve | 2335-2337 | 2335-2337 | T128 | in | TREATS | 2,335 | 2,337 | preserve | 2278-2287 | 2278-2287 | T122 | metformin | OrganicChemical | 2,278 | 2,287 | preserve | 2338-2343 | 2338-2343 | T125 | obese | DiseaseOrSyndrome | 2,338 | 2,343 | A8 | Bodyweight gain may be lessened by the concomitant use of metformin and troglitazone may improve glycaemic control in obese patients. | 2214-2353 | 2,214 | 2,353 | Bodyweight gain may be lessened by the concomitant use of @SUBJECT$ and troglitazone may improve glycaemic control @PREDICAT$ @OBJECT$ patients. |
Fact | preserve | 1253-1257 | 1253-1257 | T75 | with | PROCESS_OF | 1,253 | 1,257 | preserve | 1258-1288 | 1280-1288 | T68 | type 2 diabetes mellitus | DiseaseOrSyndrome | 1,258 | 1,288 | preserve | 1244-1252 | 1244-1252 | T67 | patients | PatientOrDisabledGroup | 1,244 | 1,252 | A9 | Reservations about insulin therapy in patients with type 2 diabetes mellitus, particularly elderly patients with cardiovascular complications, include hypoglycaemia and bodyweight gain. | 1206-1403 | 1,206 | 1,403 | Reservations about insulin therapy in @OBJECT$ @PREDICAT$ @SUBJECT$ , particularly elderly patients with cardiovascular complications, include hypoglycaemia and bodyweight gain. |
Fact | preserve | 1241-1243 | 1241-1243 | T74 | in | TREATS | 1,241 | 1,243 | preserve | 1233-1240 | 1233-1240 | T66 | therapy | TherapeuticOrPreventiveProcedure | 1,233 | 1,240 | preserve | 1244-1252 | 1244-1252 | T67 | patients | PatientOrDisabledGroup | 1,244 | 1,252 | A10 | Reservations about insulin therapy in patients with type 2 diabetes mellitus, particularly elderly patients with cardiovascular complications, include hypoglycaemia and bodyweight gain. | 1206-1403 | 1,206 | 1,403 | Reservations about insulin @SUBJECT$ @PREDICAT$ @OBJECT$ with type 2 diabetes mellitus, particularly elderly patients with cardiovascular complications, include hypoglycaemia and bodyweight gain. |
Fact | preserve | 901-903 | 901-903 | T49 | in | TREATS | 901 | 903 | preserve | 856-863 | 856-863 | T46 | insulin | AminoAcidPeptideOrProtein | 856 | 863 | preserve | 904-912 | 904-912 | T47 | patients | PatientOrDisabledGroup | 904 | 912 | A11 | Safety considerations will also point to the preferential use of insulin in other circumstances, for example, in patients with pronounced renal impairment. | 784-952 | 784 | 952 | Safety considerations will also point to the preferential use of @SUBJECT$ in other circumstances, for example, @PREDICAT$ @OBJECT$ with pronounced renal impairment. |
Probable | preserve | 1794-1796 | 1794-1796 | T98 | in | TREATS | 1,794 | 1,796 | preserve | 1768-1775 | 1768-1775 | T94 | therapy | TherapeuticOrPreventiveProcedure | 1,768 | 1,775 | preserve | 1797-1821 | 1813-1821 | T96 | type 2 diabetes mellitus | DiseaseOrSyndrome | 1,797 | 1,821 | A12 | Insulin therapy can be successful in type 2 diabetes mellitus if patients are carefully selected. | 1760-1863 | 1,760 | 1,863 | Insulin @SUBJECT$ can be successful @PREDICAT$ @OBJECT$ if patients are carefully selected. |
Fact | preserve | 2338-2352 | 2344-2352 | T127 | obese patients | PROCESS_OF | 2,338 | 2,352 | preserve | 2338-2343 | 2338-2343 | T125 | obese | DiseaseOrSyndrome | 2,338 | 2,343 | preserve | 2344-2352 | 2344-2352 | T126 | patients | PatientOrDisabledGroup | 2,344 | 2,352 | A13 | Bodyweight gain may be lessened by the concomitant use of metformin and troglitazone may improve glycaemic control in obese patients. | 2214-2353 | 2,214 | 2,353 | Bodyweight gain may be lessened by the concomitant use of metformin and troglitazone may improve glycaemic control in @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 59-61 | 59-61 | T7 | in | ASSOCIATED_WITH | 59 | 61 | preserve | 51-58 | 51-58 | T5 | insulin | AminoAcidPeptideOrProtein | 51 | 58 | preserve | 62-92 | 84-92 | T6 | type 2 diabetes mellitus | DiseaseOrSyndrome | 62 | 92 | A14 | Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. | 0-93 | 0 | 93 | Benefits and risks of transfer from oral agents to @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 913-917 | 913-917 | T50 | with | PROCESS_OF | 913 | 917 | preserve | 929-951 | 941-951 | T48 | renal impairment | DiseaseOrSyndrome | 929 | 951 | preserve | 904-912 | 904-912 | T47 | patients | PatientOrDisabledGroup | 904 | 912 | A15 | Safety considerations will also point to the preferential use of insulin in other circumstances, for example, in patients with pronounced renal impairment. | 784-952 | 784 | 952 | Safety considerations will also point to the preferential use of insulin in other circumstances, for example, in @OBJECT$ @PREDICAT$ pronounced @SUBJECT$ . |
Fact | preserve | 1486-1488 | 1486-1488 | T84 | in | PROCESS_OF | 1,486 | 1,488 | preserve | 1426-1439 | 1426-1439 | T79 | hypoglycaemia | DiseaseOrSyndrome | 1,426 | 1,439 | preserve | 1489-1497 | 1489-1497 | T82 | patients | PatientOrDisabledGroup | 1,489 | 1,497 | A16 | However, severe hypoglycaemia occurs with considerably lower frequency than in patients with type 1 diabetes mellitus. | 1404-1534 | 1,404 | 1,534 | However, severe @SUBJECT$ occurs with considerably lower frequency than @PREDICAT$ @OBJECT$ with type 1 diabetes mellitus. |
Fact | preserve | 1003-1007 | 1003-1007 | T64 | with | PROCESS_OF | 1,003 | 1,007 | preserve | 1008-1038 | 1030-1038 | T55 | type 2 diabetes mellitus | DiseaseOrSyndrome | 1,008 | 1,038 | preserve | 994-1002 | 994-1002 | T54 | patients | PatientOrDisabledGroup | 994 | 1,002 | A17 | In addition, a significant proportion of patients with type 2 diabetes mellitus will ultimately require insulin therapy in the long term because of failure of oral agents to provide adequate glycaemic control (i.e. | 953-1179 | 953 | 1,179 | In addition, a significant proportion of @OBJECT$ @PREDICAT$ @SUBJECT$ will ultimately require insulin therapy in the long term because of failure of oral agents to provide adequate glycaemic control (i.e. |
Possible | preserve | 2335-2337 | 2335-2337 | T128 | in | TREATS | 2,335 | 2,337 | preserve | 2278-2287 | 2278-2287 | T122 | metformin | OrganicChemical | 2,278 | 2,287 | preserve | 2344-2352 | 2344-2352 | T126 | patients | PatientOrDisabledGroup | 2,344 | 2,352 | A18 | Bodyweight gain may be lessened by the concomitant use of metformin and troglitazone may improve glycaemic control in obese patients. | 2214-2353 | 2,214 | 2,353 | Bodyweight gain may be lessened by the concomitant use of @SUBJECT$ and troglitazone may improve glycaemic control @PREDICAT$ obese @OBJECT$ . |
Fact | preserve | 464-471 | 464-471 | T31 | therapy | TREATS | 464 | 471 | preserve | 448-460 | 448-460 | T28 | theophylline | BiologicallyActiveSubstance | 448 | 460 | preserve | 476-479 | 476-479 | T30 | CLL | NeoplasticProcess | 476 | 479 | A1 | The clinical courses of the responders are presented, and the literature concerning theophylline as therapy for CLL is reviewed. | 357-492 | 357 | 492 | The clinical courses of the responders are presented, and the literature concerning @SUBJECT$ as @PREDICAT$ for @OBJECT$ is reviewed. |
Probable | preserve | 120-129 | 120-129 | T14 | treatment | TREATS | 120 | 129 | preserve | 70-82 | 70-82 | T5 | Theophylline | BiologicallyActiveSubstance | 70 | 82 | preserve | 134-140 | 134-140 | T8 | asthma | DiseaseOrSyndrome | 134 | 140 | A5 | Theophylline, a methylxanthine commonly used as a treatment for asthma, has been shown to induce apoptosis in chronic lymphocytic leukemia (CLL) cells both in vitro and in vivo. | 70-260 | 70 | 260 | @SUBJECT$ , a methylxanthine commonly used as a @PREDICAT$ for @OBJECT$ , has been shown to induce apoptosis in chronic lymphocytic leukemia (CLL) cells both in vitro and in vivo. |
Fact | preserve | 292-304 | 296-304 | T23 | CLL patients | PROCESS_OF | 292 | 304 | preserve | 292-295 | 292-295 | T18 | CLL | NeoplasticProcess | 292 | 295 | preserve | 296-304 | 296-304 | T19 | patients | PatientOrDisabledGroup | 296 | 304 | A8 | We have treated three advanced CLL patients with theophylline, and seen responses in two. | 261-356 | 261 | 356 | We have treated three advanced @SUBJECT$ @PREDICAT$ @OBJECT$ with theophylline, and seen responses in two. |
Fact | preserve | 821-851 | 838-851 | T58 | glucocorticoids (dexamethasone | INTERACTS_WITH | 821 | 851 | preserve | 985-1016 | 1009-1016 | T54 | corticotropin-releasing hormone | AminoAcidPeptideOrProtein | 985 | 1,016 | preserve | 838-851 | 838-851 | T46 | dexamethasone | PharmacologicSubstance | 838 | 851 | A2 | The aim of this study was to determine the effects of glucocorticoids (dexamethasone) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of neuropeptide Y and corticotropin-releasing hormone. | 761-1017 | 761 | 1,017 | The aim of this study was to determine the effects of @PREDICAT$ @OBJECT$ ) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of neuropeptide Y and @SUBJECT$ . |
Fact | preserve | 730-736 | 730-736 | T41 | within | LOCATION_OF | 730 | 736 | preserve | 747-759 | 747-759 | T40 | hypothalamus | BodyPartOrganOrOrganComponent | 747 | 759 | preserve | 700-714 | 713-714 | T38 | neuropeptide Y | AminoAcidPeptideOrProtein | 700 | 714 | A3 | Such dual action of glucocorticoids may occur within the central nervous system, since both neuropeptide Y and leptin act within the hypothalamus. | 602-760 | 602 | 760 | Such dual action of glucocorticoids may occur within the central nervous system, since both @OBJECT$ and leptin act @PREDICAT$ the @SUBJECT$ . |
Fact | preserve | 821-851 | 838-851 | T55 | glucocorticoids (dexamethasone | ISA | 821 | 851 | preserve | 838-851 | 838-851 | T46 | dexamethasone | PharmacologicSubstance | 838 | 851 | preserve | 821-836 | 821-836 | T45 | glucocorticoids | Hormone | 821 | 836 | A4 | The aim of this study was to determine the effects of glucocorticoids (dexamethasone) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of neuropeptide Y and corticotropin-releasing hormone. | 761-1017 | 761 | 1,017 | The aim of this study was to determine the effects of @OBJECT$ @PREDICAT$ @SUBJECT$ ) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of neuropeptide Y and corticotropin-releasing hormone. |
Fact | preserve | 804-811 | 804-811 | T56 | effects | INTERACTS_WITH | 804 | 811 | preserve | 985-1016 | 1009-1016 | T54 | corticotropin-releasing hormone | AminoAcidPeptideOrProtein | 985 | 1,016 | preserve | 821-836 | 821-836 | T45 | glucocorticoids | Hormone | 821 | 836 | A7 | The aim of this study was to determine the effects of glucocorticoids (dexamethasone) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of neuropeptide Y and corticotropin-releasing hormone. | 761-1017 | 761 | 1,017 | The aim of this study was to determine the @PREDICAT$ of @OBJECT$ (dexamethasone) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of neuropeptide Y and @SUBJECT$ . |
Probable | preserve | 1987-1993 | 1987-1993 | T116 | induce | CAUSES | 1,987 | 1,993 | preserve | 1965-1980 | 1965-1980 | T111 | glucocorticoids | Hormone | 1,965 | 1,980 | preserve | 2005-2013 | 2005-2013 | T113 | syndrome | DiseaseOrSyndrome | 2,005 | 2,013 | A8 | These results suggest that glucocorticoids induce an obesity syndrome in rodents by acting centrally and not peripherally. | 1938-2066 | 1,938 | 2,066 | These results suggest that @SUBJECT$ @PREDICAT$ an obesity @OBJECT$ in rodents by acting centrally and not peripherally. |
Fact | preserve | 730-736 | 730-736 | T41 | within | LOCATION_OF | 730 | 736 | preserve | 747-759 | 747-759 | T40 | hypothalamus | BodyPartOrganOrOrganComponent | 747 | 759 | preserve | 719-725 | 719-725 | T39 | leptin | AminoAcidPeptideOrProtein | 719 | 725 | A9 | Such dual action of glucocorticoids may occur within the central nervous system, since both neuropeptide Y and leptin act within the hypothalamus. | 602-760 | 602 | 760 | Such dual action of glucocorticoids may occur within the central nervous system, since both neuropeptide Y and @OBJECT$ act @PREDICAT$ the @SUBJECT$ . |
Fact | preserve | 821-851 | 838-851 | T58 | glucocorticoids (dexamethasone | INTERACTS_WITH | 821 | 851 | preserve | 960-974 | 973-974 | T53 | neuropeptide Y | AminoAcidPeptideOrProtein | 960 | 974 | preserve | 838-851 | 838-851 | T46 | dexamethasone | PharmacologicSubstance | 838 | 851 | A12 | The aim of this study was to determine the effects of glucocorticoids (dexamethasone) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of neuropeptide Y and corticotropin-releasing hormone. | 761-1017 | 761 | 1,017 | The aim of this study was to determine the effects of @PREDICAT$ @OBJECT$ ) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of @SUBJECT$ and corticotropin-releasing hormone. |
Fact | preserve | 1107-1116 | 1107-1116 | T72 | increases | AUGMENTS | 1,107 | 1,116 | preserve | 1037-1051 | 1037-1051 | T61 | glucocorticoid | Hormone | 1,037 | 1,051 | preserve | 1120-1131 | 1125-1131 | T67 | food intake | OrganismFunction | 1,120 | 1,131 | A13 | Continuous central glucocorticoid infusion for 3 days resulted in marked sustained increases in food intake and body weight relative to saline-infused controls. | 1018-1190 | 1,018 | 1,190 | Continuous central @SUBJECT$ infusion for 3 days resulted in marked sustained @PREDICAT$ in @OBJECT$ and body weight relative to saline-infused controls. |
Fact | preserve | 0-9 | 0-9 | T7 | Induction | CAUSES | 0 | 9 | preserve | 52-66 | 52-66 | T4 | glucocorticoid | Hormone | 52 | 66 | preserve | 13-20 | 13-20 | T2 | obesity | DiseaseOrSyndrome | 13 | 20 | A14 | Induction of obesity and hyperleptinemia by central glucocorticoid infusion in the rat. | 0-93 | 0 | 93 | @PREDICAT$ of @OBJECT$ and hyperleptinemia by central @SUBJECT$ infusion in the rat. |
Fact | preserve | 186-199 | 192-199 | T19 | human obesity | PROCESS_OF | 186 | 199 | preserve | 192-199 | 192-199 | T14 | obesity | DiseaseOrSyndrome | 192 | 199 | preserve | 186-191 | 186-191 | T13 | human | Human | 186 | 191 | A15 | It has been claimed that factors favoring the development or maintenance of animal or human obesity may include increases in glucocorticoid production or hyperresponsiveness of the hypothalamic-pituitary-adrenal axis. | 94-323 | 94 | 323 | It has been claimed that factors favoring the development or maintenance of animal or @OBJECT$ @PREDICAT$ @SUBJECT$ may include increases in glucocorticoid production or hyperresponsiveness of the hypothalamic-pituitary-adrenal axis. |
Fact | preserve | 804-811 | 804-811 | T56 | effects | INTERACTS_WITH | 804 | 811 | preserve | 960-974 | 973-974 | T53 | neuropeptide Y | AminoAcidPeptideOrProtein | 960 | 974 | preserve | 821-836 | 821-836 | T45 | glucocorticoids | Hormone | 821 | 836 | A16 | The aim of this study was to determine the effects of glucocorticoids (dexamethasone) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of neuropeptide Y and corticotropin-releasing hormone. | 761-1017 | 761 | 1,017 | The aim of this study was to determine the @PREDICAT$ of @OBJECT$ (dexamethasone) given intracerebroventricularly to normal rats on body weight homeostasis and hypothalamic levels of @SUBJECT$ and corticotropin-releasing hormone. |
Fact | preserve | 466-473 | 466-473 | T29 | produce | CAUSES | 466 | 473 | preserve | 448-462 | 461-462 | T26 | neuropeptide Y | AminoAcidPeptideOrProtein | 448 | 462 | preserve | 474-481 | 474-481 | T27 | obesity | DiseaseOrSyndrome | 474 | 481 | A17 | In normal rats, glucocorticoids have been shown to be necessary for chronic intracerebroventricular infusion of neuropeptide Y to produce obesity and related abnormalities. | 324-514 | 324 | 514 | In normal rats, glucocorticoids have been shown to be necessary for chronic intracerebroventricular infusion of @SUBJECT$ to @PREDICAT$ @OBJECT$ and related abnormalities. |
Fact | preserve | 2014-2016 | 2014-2016 | T117 | in | PROCESS_OF | 2,014 | 2,016 | preserve | 2005-2013 | 2005-2013 | T113 | syndrome | DiseaseOrSyndrome | 2,005 | 2,013 | preserve | 2017-2024 | 2017-2024 | T114 | rodents | Mammal | 2,017 | 2,024 | A18 | These results suggest that glucocorticoids induce an obesity syndrome in rodents by acting centrally and not peripherally. | 1938-2066 | 1,938 | 2,066 | These results suggest that glucocorticoids induce an obesity @SUBJECT$ @PREDICAT$ @OBJECT$ by acting centrally and not peripherally. |
Fact | preserve | 1690-1706 | 1699-1706 | T85 | valvular disease | LOCATION_OF | 1,690 | 1,706 | preserve | 1690-1698 | 1690-1698 | T82 | valvular | BodyPartOrganOrOrganComponent | 1,690 | 1,698 | preserve | 1699-1706 | 1699-1706 | T83 | disease | DiseaseOrSyndrome | 1,699 | 1,706 | A3 | Other interventions include the selective use of beta blockers, adequate analgesia for all, control of hypertension, and appropriate volume management, especially in the settings of preexisting CHF or valvular disease. | 1477-1707 | 1,477 | 1,707 | Other interventions include the selective use of beta blockers, adequate analgesia for all, control of hypertension, and appropriate volume management, especially in the settings of preexisting CHF or @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 2716-2720 | 2716-2720 | T135 | risk | PREDISPOSES | 2,716 | 2,720 | preserve | 2693-2701 | 2693-2701 | T131 | Diabetes | DiseaseOrSyndrome | 2,693 | 2,701 | preserve | 2730-2739 | 2730-2739 | T133 | infection | DiseaseOrSyndrome | 2,730 | 2,739 | A4 | Diabetes increases the risk of infection and cardiac complications. | 2693-2766 | 2,693 | 2,766 | @SUBJECT$ increases the @PREDICAT$ of @OBJECT$ and cardiac complications. |
Fact | preserve | 2299-2303 | 2299-2303 | T130 | with | PROCESS_OF | 2,299 | 2,303 | preserve | 2324-2332 | 2324-2332 | T114 | diseases | DiseaseOrSyndrome | 2,324 | 2,332 | preserve | 2290-2298 | 2290-2298 | T112 | Patients | PatientOrDisabledGroup | 2,290 | 2,298 | A5 | Patients with rheumatologic diseases have specific concerns based on systemic manifestations of disease including anemia, thrombocytopenia, pulmonary fibrosis, pericarditis, and hypercoagulability; medication effects particularly from steroids and nonsteroidal anti-inflammatory drugs; and specific joint problems including contractures and atlantoaxial joint instability. | 2290-2692 | 2,290 | 2,692 | @OBJECT$ @PREDICAT$ rheumatologic @SUBJECT$ have specific concerns based on systemic manifestations of disease including anemia, thrombocytopenia, pulmonary fibrosis, pericarditis, and hypercoagulability; medication effects particularly from steroids and nonsteroidal anti-inflammatory drugs; and specific joint problems including contractures and atlantoaxial joint instability. |
Fact | preserve | 1190-1197 | 1190-1197 | T61 | benefit | TREATS | 1,190 | 1,197 | preserve | 1222-1239 | 1222-1239 | T60 | revascularization | TherapeuticOrPreventiveProcedure | 1,222 | 1,239 | preserve | 1176-1184 | 1176-1184 | T58 | patients | PatientOrDisabledGroup | 1,176 | 1,184 | A6 | Clinical variables are optimally combined with selective stress testing to discern which patients will benefit from preoperative revascularization. | 1081-1240 | 1,081 | 1,240 | Clinical variables are optimally combined with selective stress testing to discern which @OBJECT$ will @PREDICAT$ from preoperative @SUBJECT$ . |
Fact | preserve | 1592-1594 | 1592-1594 | T100 | of | PART_OF | 1,592 | 1,594 | preserve | 1584-1591 | 1584-1591 | T93 | kidneys | BodyPartOrganOrOrganComponent | 1,584 | 1,591 | preserve | 1595-1599 | 1595-1599 | T94 | rats | Mammal | 1,595 | 1,599 | A1 | Arteriolar fibrinoid necrosis was a prominent feature in kidneys of rats infused with AII from 4 to 8 weeks after TBI. | 1521-1645 | 1,521 | 1,645 | Arteriolar fibrinoid necrosis was a prominent feature in @SUBJECT$ @PREDICAT$ @OBJECT$ infused with AII from 4 to 8 weeks after TBI. |
Fact | preserve | 1521-1550 | 1542-1550 | T98 | Arteriolar fibrinoid necrosis | LOCATION_OF | 1,521 | 1,550 | preserve | 1521-1531 | 1521-1531 | T90 | Arteriolar | BodyPartOrganOrOrganComponent | 1,521 | 1,531 | preserve | 1532-1550 | 1542-1550 | T91 | fibrinoid necrosis | PathologicFunction | 1,532 | 1,550 | A2 | Arteriolar fibrinoid necrosis was a prominent feature in kidneys of rats infused with AII from 4 to 8 weeks after TBI. | 1521-1645 | 1,521 | 1,645 | @SUBJECT$ @PREDICAT$ @OBJECT$ was a prominent feature in kidneys of rats infused with AII from 4 to 8 weeks after TBI. |
Fact | preserve | 1123-1129 | 1123-1129 | T64 | caused | CAUSES | 1,123 | 1,129 | preserve | 1111-1122 | 1111-1122 | T57 | Irradiation | TherapeuticOrPreventiveProcedure | 1,111 | 1,122 | preserve | 1143-1155 | 1143-1155 | T59 | hypertension | DiseaseOrSyndrome | 1,143 | 1,155 | A3 | Irradiation caused azotemia and hypertension, which were not exacerbated by AII infusion at 200 ng/kg/min. | 1111-1223 | 1,111 | 1,223 | @SUBJECT$ @PREDICAT$ azotemia and @OBJECT$ , which were not exacerbated by AII infusion at 200 ng/kg/min. |
Counterfact | preserve | 1178-1189 | 1178-1189 | T66 | exacerbated | AFFECTS | 1,178 | 1,189 | preserve | 1193-1196 | 1193-1196 | T61 | AII | AminoAcidPeptideOrProtein | 1,193 | 1,196 | preserve | 1143-1155 | 1143-1155 | T59 | hypertension | DiseaseOrSyndrome | 1,143 | 1,155 | A4 | Irradiation caused azotemia and hypertension, which were not exacerbated by AII infusion at 200 ng/kg/min. | 1111-1223 | 1,111 | 1,223 | Irradiation caused azotemia and @OBJECT$ , which were not @PREDICAT$ by @SUBJECT$ infusion at 200 ng/kg/min. |
Fact | preserve | 1980-2015 | 2007-2015 | T129 | arteriolar fibrinoid necrosis | LOCATION_OF | 1,980 | 2,015 | preserve | 1980-1990 | 1980-1990 | T120 | arteriolar | BodyPartOrganOrOrganComponent | 1,980 | 1,990 | preserve | 1991-2015 | 2007-2015 | T121 | fibrinoid necrosis | PathologicFunction | 1,991 | 2,015 | A5 | The occurrence of arteriolar fibrinoid necrosis in the irradiated, 4-to-8-week-infused animals suggests that vascular injury during that interval determines later outcome. | 1962-2145 | 1,962 | 2,145 | The occurrence of @SUBJECT$ @PREDICAT$ @OBJECT$ in the irradiated, 4-to-8-week-infused animals suggests that vascular injury during that interval determines later outcome. |
Fact | preserve | 2016-2018 | 2016-2018 | T130 | in | PROCESS_OF | 2,016 | 2,018 | preserve | 1991-2015 | 2007-2015 | T121 | fibrinoid necrosis | PathologicFunction | 1,991 | 2,015 | preserve | 2055-2062 | 2055-2062 | T124 | animals | Animal | 2,055 | 2,062 | A8 | The occurrence of arteriolar fibrinoid necrosis in the irradiated, 4-to-8-week-infused animals suggests that vascular injury during that interval determines later outcome. | 1962-2145 | 1,962 | 2,145 | The occurrence of arteriolar @SUBJECT$ @PREDICAT$ the irradiated, 4-to-8-week-infused @OBJECT$ suggests that vascular injury during that interval determines later outcome. |
Fact | preserve | 1123-1129 | 1123-1129 | T64 | caused | CAUSES | 1,123 | 1,129 | preserve | 1111-1122 | 1111-1122 | T57 | Irradiation | TherapeuticOrPreventiveProcedure | 1,111 | 1,122 | preserve | 1130-1138 | 1130-1138 | T58 | azotemia | DiseaseOrSyndrome | 1,130 | 1,138 | A9 | Irradiation caused azotemia and hypertension, which were not exacerbated by AII infusion at 200 ng/kg/min. | 1111-1223 | 1,111 | 1,223 | @SUBJECT$ @PREDICAT$ @OBJECT$ and hypertension, which were not exacerbated by AII infusion at 200 ng/kg/min. |
Counterfact | preserve | 979-984 | 979-984 | T50 | cause | CAUSES | 979 | 984 | preserve | 952-955 | 952-955 | T46 | AII | AminoAcidPeptideOrProtein | 952 | 955 | preserve | 991-999 | 991-999 | T49 | azotemia | DiseaseOrSyndrome | 991 | 999 | A10 | AII infusion alone did not cause azotemia. | 952-1000 | 952 | 1,000 | @SUBJECT$ infusion alone did not @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1575-1577 | 1575-1577 | T99 | in | LOCATION_OF | 1,575 | 1,577 | preserve | 1584-1591 | 1584-1591 | T93 | kidneys | BodyPartOrganOrOrganComponent | 1,584 | 1,591 | preserve | 1532-1550 | 1542-1550 | T91 | fibrinoid necrosis | PathologicFunction | 1,532 | 1,550 | A13 | Arteriolar fibrinoid necrosis was a prominent feature in kidneys of rats infused with AII from 4 to 8 weeks after TBI. | 1521-1645 | 1,521 | 1,645 | Arteriolar @OBJECT$ was a prominent feature @PREDICAT$ @SUBJECT$ of rats infused with AII from 4 to 8 weeks after TBI. |
Fact | preserve | 24-35 | 24-35 | T5 | exacerbates | AFFECTS | 24 | 35 | preserve | 0-14 | 0-11 | T1 | Angiotensin II | AminoAcidPeptideOrProtein | 0 | 14 | preserve | 46-57 | 46-57 | T4 | nephropathy | DiseaseOrSyndrome | 46 | 57 | A14 | Angiotensin II infusion exacerbates radiation nephropathy. | 0-58 | 0 | 58 | @SUBJECT$ infusion @PREDICAT$ radiation @OBJECT$ . |
Fact | preserve | 100-110 | 100-110 | T11 | exacerbate | AFFECTS | 100 | 110 | preserve | 80-94 | 80-91 | T7 | angiotensin II | AminoAcidPeptideOrProtein | 80 | 94 | preserve | 121-132 | 121-132 | T9 | nephropathy | DiseaseOrSyndrome | 121 | 132 | A15 | We hypothesized that angiotensin II will exacerbate radiation nephropathy in a time-specific manner. | 59-165 | 59 | 165 | We hypothesized that @SUBJECT$ will @PREDICAT$ radiation @OBJECT$ in a time-specific manner. |
Counterfact | preserve | 1178-1189 | 1178-1189 | T66 | exacerbated | AFFECTS | 1,178 | 1,189 | preserve | 1193-1196 | 1193-1196 | T61 | AII | AminoAcidPeptideOrProtein | 1,193 | 1,196 | preserve | 1130-1138 | 1130-1138 | T58 | azotemia | DiseaseOrSyndrome | 1,130 | 1,138 | A16 | Irradiation caused azotemia and hypertension, which were not exacerbated by AII infusion at 200 ng/kg/min. | 1111-1223 | 1,111 | 1,223 | Irradiation caused @OBJECT$ and hypertension, which were not @PREDICAT$ by @SUBJECT$ infusion at 200 ng/kg/min. |